Emerging Paradigms in Immune-Focused Drug Discovery
Related Experiment Video
Updated: Mar 19, 2026

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Anna C Renner1, Robert B Kargbo2
1North Dakota State University, Fargo, North Dakota 58108-6050, United States.
Abstract:
Recent patent disclosures highlight a conceptual shift in drug discovery, integrating targeted protein degradation with functional precision oncology. IRAK-M and IRAK4 degraders exemplify how innate immune signaling can be rewired through selective protein removal, while patient-derived microcancer platforms provide a decision framework for rationally deploying such agents. Together, these inventions redefine how molecular precision and biological context converge to guide translational success.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Tumor Immunotherapy

